Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CALML3 | P27482 | 6/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455754 | 0.83 | HRH3 (0.45) | MAOBHRH3HRH1CYP2D6 | |
| SCHEMBL6192208 | 0.82 | MAOA (0.57) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL14440468 | 0.82 | GRM2 (0.47) | HRH3HRH1CYP2D6 | |
| SCHEMBL2184129 | 0.82 | MAOA (0.55) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL2184137 | 0.82 | MAOA (0.55) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL5456739 | 0.80 | GRM2 (0.51) | HRH3HRH1CYP2D6 | |
| SCHEMBL6213449 | 0.78 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6192445 | 0.78 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6210714 | 0.78 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6210718 | 0.78 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | MAOA 59/4885MAOB 19/4885CALML3 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.